These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28900008)

  • 21. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
    Deronic A; Tahvili S; Leanderson T; Ivars F
    BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.
    Ngamsri KC; Jans C; Putri RA; Schindler K; Gamper-Tsigaras J; Eggstein C; Köhler D; Konrad FM
    Front Immunol; 2020; 11():407. PubMed ID: 32210974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment.
    Garibaldi BT; D'Alessio FR; Mock JR; Files DC; Chau E; Eto Y; Drummond MB; Aggarwal NR; Sidhaye V; King LS
    Am J Respir Cell Mol Biol; 2013 Jan; 48(1):35-43. PubMed ID: 23002097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.
    Hu Y; Gale M; Shields J; Garron C; Swistak M; Nguyen TH; Jacques G; Fogle R; Siders W; Kaplan J
    Leuk Lymphoma; 2012 Jan; 53(1):130-8. PubMed ID: 21740294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ly6C
    Schloss MJ; Hilby M; Nitz K; Guillamat Prats R; Ferraro B; Leoni G; Soehnlein O; Kessler T; He W; Luckow B; Horckmans M; Weber C; Duchene J; Steffens S
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1640-1645. PubMed ID: 28663258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.
    Gagner JP; Sarfraz Y; Ortenzi V; Alotaibi FM; Chiriboga LA; Tayyib AT; Douglas GJ; Chevalier E; Romagnoli B; Tuffin G; Schmitt M; Lemercier G; Dembowsky K; Zagzag D
    Am J Pathol; 2017 Sep; 187(9):2080-2094. PubMed ID: 28734730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
    Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
    Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
    Khare T; Bissonnette M; Khare S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
    Varey AH; Rennel ES; Qiu Y; Bevan HS; Perrin RM; Raffy S; Dixon AR; Paraskeva C; Zaccheo O; Hassan AB; Harper SJ; Bates DO
    Br J Cancer; 2008 Apr; 98(8):1366-79. PubMed ID: 18349829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VEGF Production by Ly6C+high Monocytes Contributes to Ventilator-Induced Lung Injury.
    Shi CS; Huang TH; Lin CK; Li JM; Chen MH; Tsai ML; Chang CC
    PLoS One; 2016; 11(10):e0165317. PubMed ID: 27783650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
    Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
    Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
    Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
    Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
    Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.